Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:BLPH
- CUSIP: N/A
- Web: www.bellerophon.com
- Market Cap: $44.21 million
- Outstanding Shares: 32,039,000
- 50 Day Moving Avg: $1.41
- 200 Day Moving Avg: $1.04
- 52 Week Range: $0.43 - $4.58
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.22
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.57 per share
- Price / Book: 2.42
- EBIDTA: ($23,710,000.00)
- Return on Equity: -117.99%
- Return on Assets: -91.74%
- Current Ratio: 3.67%
- Quick Ratio: 3.67%
- Average Volume: 1.03 million shs.
- Beta: -2.64
- Short Ratio: 2.09
Frequently Asked Questions for Bellerophon Therapeutics (NASDAQ:BLPH)
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics Inc (NASDAQ:BLPH) released its earnings results on Monday, May, 15th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. View Bellerophon Therapeutics' Earnings History.
Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?
3 brokers have issued 1 year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $4.50 to $5.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $4.75 in the next twelve months. View Analyst Ratings for Bellerophon Therapeutics.
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Infinity Pharmaceuticals (INFI), Verastem (VSTM), AVEO Pharmaceuticals (AVEO), Microbot Medical (MBOT), Ophthotech Corp (OPHT), ArQule (ARQL), Mirati Therapeutics (MRTX), aTyr Pharma (LIFE), Akari Therapeutics PLC (AKTX), Actinium Pharmaceuticals (ATNM), Cellular Biomedicine Group (CBMG), Nexvet Biopharma plc (NVET), Brainstorm Cell Therapeutics (BCLI), Intec Pharma Ltd (NTEC), Regulus Therapeutics (RGLS), Navidea Biopharmaceuticals (NAVB), Xenon Pharmaceuticals (XENE) and Dicerna Pharmaceuticals (DRNA).
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Who owns Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
CVI INVESTMENTS, INC.
BOXER CAPITAL, LLC
(5.90%), Boxer Capital LLC (5.80%), FMR LLC (3.57%), Renaissance Technologies LLC (1.49%) and Vanguard Group Inc. (1.25%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock. View Institutional Ownership Trends for Bellerophon Therapeutics.
Who sold Bellerophon Therapeutics stock? Who is selling Bellerophon Therapeutics stock?
Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock. View Insider Buying and Selling for Bellerophon Therapeutics.
How do I buy Bellerophon Therapeutics stock?
Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bellerophon Therapeutics stock cost?
One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.38.
Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)Earnings History by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)
2017 EPS Consensus Estimate: ($1.08)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Bellerophon Therapeutics (NASDAQ:BLPH)
Insider Ownership Percentage: 54.20%Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Institutional Ownership Percentage: 44.60%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/9/2016||Jens Luehring||Director||Buy||20,000||$0.56||$11,200.00|| |
|5/17/2016||Jonathan M Peacock||CEO||Buy||5,000||$1.37||$6,850.00|| |
|12/16/2015||Jonathan M. Peacock||CEO||Buy||20,300||$2.75||$55,825.00|| |
|8/19/2015||Jonathan M Peacock||CEO||Buy||5,000||$5.48||$27,400.00|| |
|5/20/2015||Jonathan M Peacock||CEO||Buy||5,560||$8.69||$48,316.40|| |
|2/19/2015||Daniel Tasse||Director||Buy||25,000||$12.00||$300,000.00|| |
|2/19/2015||Jonathan M Peacock||CEO||Buy||20,800||$12.00||$249,600.00|| |
|2/19/2015||Linde North America, Inc.||Major Shareholder||Buy||358,916||$12.00||$4,306,992.00|| |
|2/19/2015||Manesh Naidu||Insider||Buy||1,500||$12.00||$18,000.00|| |
Headline Trends for Bellerophon Therapeutics (NASDAQ:BLPH)
Latest Headlines for Bellerophon Therapeutics (NASDAQ:BLPH)
|Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics|
www.bizjournals.com - May 25 at 10:04 PM
|Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)|
www.prnewswire.com - May 25 at 5:01 PM
|Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.com|
www.streetinsider.com - May 24 at 8:53 PM
|Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse|
www.streetinsider.com - May 23 at 11:51 AM
|Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference|
finance.yahoo.com - May 23 at 11:51 AM
|Bellerophon Therapeutics Inc (BLPH) Issues Quarterly Earnings Results|
www.americanbankingnews.com - May 16 at 3:24 PM
|Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)|
globenewswire.com - May 15 at 9:41 AM
|Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update|
finance.yahoo.com - May 15 at 9:40 AM
|Bellerophon Therapeutics posts 1Q loss|
finance.yahoo.com - May 15 at 9:40 AM
|BRIEF-Bellerophon to issue 2 mln registered shares of common stock|
www.reuters.com - May 11 at 4:29 PM
|Bellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, Warrants|
www.streetinsider.com - May 11 at 9:15 AM
|Bellerophon Announces $3.0 Million Registered Direct Offering|
finance.yahoo.com - May 10 at 8:48 AM
|Bellerophon Therapeutics Inc (BLPH) to Release Quarterly Earnings on Monday|
www.americanbankingnews.com - May 6 at 12:16 AM
|Bellerophon Therapeutics Inc (BLPH) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - May 5 at 11:54 PM
|Bellerophon Therapeutics (BLPH) Earns Daily News Impact Rating of 0.34|
www.americanbankingnews.com - May 2 at 12:52 PM
|Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.com|
www.streetinsider.com - May 2 at 11:49 AM
|Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS|
www.streetinsider.com - May 1 at 3:57 PM
|Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference|
finance.yahoo.com - May 1 at 9:09 AM
|Bellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Report Finds|
www.americanbankingnews.com - April 28 at 10:22 AM
|Bellerophon Therapeutics (BLPH) Earning Somewhat Critical Media Coverage, Report Shows|
www.americanbankingnews.com - April 24 at 6:08 PM
|Bellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Analysis Finds|
www.americanbankingnews.com - April 21 at 12:33 PM
|Bellerophon Therapeutics Inc (BLPH) Short Interest Down 0.6% in March|
www.americanbankingnews.com - April 20 at 7:54 PM
|Bellerophon Therapeutics (BLPH) Given Daily Coverage Optimism Rating of 0.10|
www.americanbankingnews.com - April 17 at 2:08 PM
|Bellerophon Therapeutics Inc (BLPH) Receives New Coverage from Analysts at Ladenburg Thalmann Financial Services|
www.americanbankingnews.com - April 17 at 9:51 AM
|Bellerophon Therapeutics (BLPH) Receiving Somewhat Negative Press Coverage, Analysis Finds|
www.americanbankingnews.com - April 14 at 7:58 AM
|Bellerophon Slumps on Underwhelming INOpulse Data|
finance.yahoo.com - April 7 at 3:53 PM
|Bellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulseÂ® for Pulmonary Arterial Hypertension at ... - StreetInsider.com|
www.streetinsider.com - April 7 at 8:34 AM
|Short Interest in Bellerophon Therapeutics Inc (BLPH) Grows By 43.6%|
www.americanbankingnews.com - March 28 at 8:23 AM
|Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation|
finance.yahoo.com - March 27 at 11:40 AM
|The Difference Between Spectacular News and No News|
finance.yahoo.com - March 21 at 4:18 PM
|BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an|
biz.yahoo.com - March 16 at 3:17 PM
|BELLEROPHON THERAPEUTICS, INC. Financials|
finance.yahoo.com - March 16 at 3:17 PM
|Bellerophon Therapeutics Inc (BLPH) Announces Quarterly Earnings Results|
www.americanbankingnews.com - March 14 at 9:58 AM
|APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX|
www.nasdaq.com - March 14 at 8:42 AM
|BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report|
us.rd.yahoo.com - March 13 at 11:49 AM
|Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update|
us.rd.yahoo.com - March 13 at 11:49 AM
|BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement|
biz.yahoo.com - March 13 at 11:49 AM
|LifeSci Capital Initiates Coverage of Bellerophon Therapeutics|
finance.yahoo.com - February 23 at 3:55 PM
|18 Biggest Mid-Day Gainers For Tuesday - Benzinga|
www.benzinga.com - February 21 at 3:16 PM
|Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright|
finance.yahoo.com - January 20 at 5:01 PM
Bellerophon Therapeutics (BLPH) Chart for Thursday, May, 25, 2017